Chris Watson1,2,3, J Paul Spiers4, Max Waterstone4, Adam Russell-Hallinan2, Joseph Gallagher1,3, Kenneth McDonald1,3, Cristin Ryan5, John Gilmer5, Mark Ledwidge6,7. 1. STOP-HF Unit, St. Vincent's University Healthcare Group, Dublin, Ireland. 2. Wellcome-Wolfson Institute for Experimental Medicine, Queen's University , Belfast, Northern Ireland. 3. School of Medicine, University College Dublin, Dublin, Ireland. 4. Department of Pharmacology and Therapeutics, Trinity College Dublin, Dublin, Ireland. 5. School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland. 6. STOP-HF Unit, St. Vincent's University Healthcare Group, Dublin, Ireland. mark.ledwidge@ucd.ie. 7. School of Medicine, University College Dublin, Dublin, Ireland. mark.ledwidge@ucd.ie.
Abstract
BACKGROUND: Hypertension and/or myocardial infarction are common causes of heart failure in Type 2 diabetes. Progression to heart failure is usually preceded by ventricular dysfunction, linked to matrix metalloproteinase (MMP) mediated extracellular matrix changes. We hypothesise that the minor allele of genetic variant rs3918242 in the promoter region of the MMP-9 gene is associated with hypertension and/or myocardial infarction, with resultant progression of dysfunctional cardiac remodelling in patients with diabetes without symptomatic heart failure. METHODS: We genotyped 498 diabetes patients participating in the St Vincent's Screening TO Prevent Heart Failure (STOP-HF) follow-up programme for the rs3918242 single nucleotide polymorphism and investigated associations with the co-primary endpoints hypertension and/or myocardial infarction using a dominant model. We also evaluated resulting cardiometabolic phenotype and progression of ventricular dysfunction and cardiac structural abnormalities over a median follow-up period of 3.5 years. RESULTS: The CT/TT genotype comprised 28.1% of the cohort and was associated with a twofold higher risk of myocardial infarction (17.9% vs 8.4%), a reduction in ejection fraction and greater left ventricular systolic dysfunction progression [adjusted OR = 2.56 (1.09, 6.01), p = 0.026] over a median follow-up of 3.5 years [IQR 2.6, 4.9 years]. Conversely, rs3918242 was not associated with hypertension, blood pressure, pulse pressure or left ventricular mass index at baseline or over follow up. CONCLUSIONS: Diabetes patients with the minor T allele of rs3918242 in the STOP-HF follow up programme have greater risk of myocardial infarction, lower ejection fraction and greater progression of left ventricular systolic abnormalities, a precursor to heart failure. These data may support further work on MMP-9 as a biomarker of ventricular dysfunction and the investigation of MMP-9 inhibitors for heart failure prevention in diabetes, particularly in the post-infarction setting. ClinicalTrials.gov Identifier: NCT00921960.
BACKGROUND:Hypertension and/or myocardial infarction are common causes of heart failure in Type 2 diabetes. Progression to heart failure is usually preceded by ventricular dysfunction, linked to matrix metalloproteinase (MMP) mediated extracellular matrix changes. We hypothesise that the minor allele of genetic variant rs3918242 in the promoter region of the MMP-9 gene is associated with hypertension and/or myocardial infarction, with resultant progression of dysfunctional cardiac remodelling in patients with diabetes without symptomatic heart failure. METHODS: We genotyped 498 diabetespatients participating in the St Vincent's Screening TO Prevent Heart Failure (STOP-HF) follow-up programme for the rs3918242 single nucleotide polymorphism and investigated associations with the co-primary endpoints hypertension and/or myocardial infarction using a dominant model. We also evaluated resulting cardiometabolic phenotype and progression of ventricular dysfunction and cardiac structural abnormalities over a median follow-up period of 3.5 years. RESULTS: The CT/TT genotype comprised 28.1% of the cohort and was associated with a twofold higher risk of myocardial infarction (17.9% vs 8.4%), a reduction in ejection fraction and greater left ventricular systolic dysfunction progression [adjusted OR = 2.56 (1.09, 6.01), p = 0.026] over a median follow-up of 3.5 years [IQR 2.6, 4.9 years]. Conversely, rs3918242 was not associated with hypertension, blood pressure, pulse pressure or left ventricular mass index at baseline or over follow up. CONCLUSIONS:Diabetespatients with the minor T allele of rs3918242 in the STOP-HF follow up programme have greater risk of myocardial infarction, lower ejection fraction and greater progression of left ventricular systolic abnormalities, a precursor to heart failure. These data may support further work on MMP-9 as a biomarker of ventricular dysfunction and the investigation of MMP-9 inhibitors for heart failure prevention in diabetes, particularly in the post-infarction setting. ClinicalTrials.gov Identifier: NCT00921960.
Authors: Jialiang Hu; Philippe E Van den Steen; Qing-Xiang A Sang; Ghislain Opdenakker Journal: Nat Rev Drug Discov Date: 2007-06 Impact factor: 84.694
Authors: Cesar A Meschiari; Mira Jung; Rugmani Padmanabhan Iyer; Andriy Yabluchanskiy; Hiroe Toba; Michael R Garrett; Merry L Lindsey Journal: Am J Physiol Heart Circ Physiol Date: 2017-10-13 Impact factor: 4.733
Authors: Mark Ledwidge; Joseph Gallagher; Carmel Conlon; Elaine Tallon; Eoin O'Connell; Ian Dawkins; Chris Watson; Rory O'Hanlon; Margaret Bermingham; Anil Patle; Mallikarjuna R Badabhagni; Gillian Murtagh; Victor Voon; Leslie Tilson; Michael Barry; Laura McDonald; Brian Maurer; Kenneth McDonald Journal: JAMA Date: 2013-07-03 Impact factor: 56.272
Authors: Laura Ernande; Cyrille Bergerot; Ernst R Rietzschel; Marc L De Buyzere; Hélène Thibault; Pierre Gautier Pignonblanc; Pierre Croisille; Michel Ovize; Laure Groisne; Philippe Moulin; Thierry C Gillebert; Geneviève Derumeaux Journal: J Am Soc Echocardiogr Date: 2011-09-09 Impact factor: 5.251
Authors: Christophe Bauters; Nicolas Lamblin; Pierre V Ennezat; Christophe Mycinski; Olivier Tricot; Olivier Nugue; Benoit Segrestin; Gery Hannebicque; Benaissa Agraou; Anne Sophie Polge; Pascal de Groote; Nicole Helbecque; Philippe Amouyel Journal: Am Heart J Date: 2007-04 Impact factor: 4.749